Companies exploring the use of hybrid or decentralized trials during this new era of drug development are encouraged to join this webinar for an interactive panel session featuring leaders from across the industry to learn from their direct experience.
During this event, panelists will explore ways in which hybrid and decentralized trials have altered traditional clinical pathways and the new landscape that sponsors, sites and patients must navigate as a result of the COVID-19 pandemic. The panelists will also highlight the challenges and opportunities with transitioning to a hybrid or decentralized trial strategy and what they would recommend for those planning to do the same. Topics will include, but are not limited to, data integrity, key stakeholders, trial design, operational considerations, essential infrastructure and insights into both the role and value these types of trials will have in the future.
Register today for this informative panel discussion to increase understanding of hybrid and decentralized trials as well as their impact to clinical research.
Niklas Morton serves as senior vice president of PPD Digital. In this role, he oversees the operations and delivery of digitally enabled and decentralized/virtual studies, along with PPD’s robotic automation capabilities. Since joining PPD in 1998 as a biostatistics manager, Morton has advanced through various roles of increasing leadership and responsibility within the company. He spent nearly five years in PPD’s project management department, where he had section-head responsibility for PPD’s Europe, Middle East and Africa (EMEA) hematology/oncology group.
Brittany Erana, M.P.M., is vice president and head of operations for PPD’s digital services. In this role, she’s responsible for setting the vision and designing the operational infrastructure and capabilities necessary to successfully deliver decentralized and digitally-enabled clinical trials while upholding quality. Erana brings more than 15 years of broad industry experience in global research operations and strategy, digital implementation project and program delivery. She holds a Bachelor of Arts in psychology from East Carolina University, a master’s degree in project management from Western Carolina University and a certificate in international business from University College Dublin Smurfit Business School.
Dr. Longmire is a Stanford-trained physician and entrepreneur driven to improve human health through advances in technology. Dr. Longmire founded Medable in 2015 to enable effective therapies to reach patients faster by advancing clinical trials with digital technologies.
David Coman is the chief executive officer of Science 37, which makes it easier for people to participate in clinical research by connecting patients with doctors and nurses through telemedicine visits and home health screenings, then managing trial logistics from an integrated, comprehensive platform.
David came to Science 37 from ERT, where he led its data and analytics business after serving as the company’s chief strategy officer. As the leader of ERT’s data and analytics business, David reimagined the way the pharmaceutical industry looks at performance and risk management for clinical trials while more than doubling the company’s bookings from analytics over a two-year period. In his strategy role, David spearheaded the acquisition of four companies in a 12-month period, generating more than $1 billion in enterprise value, while repositioning ERT as the market leader in clinical trial data generation.
Trinette Mitchell is Head of Clinical Trial Innovation at Takeda Pharmaceuticals where she leads a team focused on eClinical trial tools for decentralized trials. With a background in clinical data solutions and partnership management, Trinette has a talent for transforming the business process through the implementation of innovative technology.
Arsalan Arif is a news media entrepreneur who set out in 2015 to build his vision of an independent biotech news company at Endpoints News.